The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Daniel Brissaud - One of the best experts on this subject based on the ideXlab platform.
-
a tool to implement sustainable end of life strategies in the product Development Phase
Journal of Cleaner Production, 2008Co-Authors: Alexis Gehin, Peggy Zwolinski, Daniel BrissaudAbstract:Responding to constantly more demanding European legislation, notably for electrical and electronic equipment, worn-out vehicles or hazardous substances, manufacturers have to develop End of Life (EoL) strategies. The challenge today is to assess which ''product EoL process'' would be profitable for an enterprise given the business model in place. Most of the Original Equipment Manufacturers recycle or subcontract reverse logistic and EoL treatments. Recycling is currently the most common solution but it is far from meeting the goals of Sustainable Development. We believe that, integrating constraints from EoL strategies into the early Phases of design is one important aspect that needs to be improved. We are currently combining this idea with principles from concurrent engineering to develop design aids which permits designers to compare their products to ''Remanufacturable Product Profiles''. However, conscious those EoL solutions often involve several strategies; it is now envisaged to develop tools to help designers make optimal decisions while designing a product considering 3R strategies: Reuse, Remanufacture and Recycle. In this paper, our vision of why and how to integrate EoL strategies in the early design Phases is presented, and what tools to apply 3R strategies are envisaged, considering the evolving architecture of the product, and the translation of transversal information into design criteria.
Alexis Gehin - One of the best experts on this subject based on the ideXlab platform.
-
a tool to implement sustainable end of life strategies in the product Development Phase
Journal of Cleaner Production, 2008Co-Authors: Alexis Gehin, Peggy Zwolinski, Daniel BrissaudAbstract:Responding to constantly more demanding European legislation, notably for electrical and electronic equipment, worn-out vehicles or hazardous substances, manufacturers have to develop End of Life (EoL) strategies. The challenge today is to assess which ''product EoL process'' would be profitable for an enterprise given the business model in place. Most of the Original Equipment Manufacturers recycle or subcontract reverse logistic and EoL treatments. Recycling is currently the most common solution but it is far from meeting the goals of Sustainable Development. We believe that, integrating constraints from EoL strategies into the early Phases of design is one important aspect that needs to be improved. We are currently combining this idea with principles from concurrent engineering to develop design aids which permits designers to compare their products to ''Remanufacturable Product Profiles''. However, conscious those EoL solutions often involve several strategies; it is now envisaged to develop tools to help designers make optimal decisions while designing a product considering 3R strategies: Reuse, Remanufacture and Recycle. In this paper, our vision of why and how to integrate EoL strategies in the early design Phases is presented, and what tools to apply 3R strategies are envisaged, considering the evolving architecture of the product, and the translation of transversal information into design criteria.
Marieke J Schuurmans - One of the best experts on this subject based on the ideXlab platform.
-
increasing value and reducing waste by optimizing the Development of complex interventions enriching the Development Phase of the medical research council mrc framework
International Journal of Nursing Studies, 2018Co-Authors: Nienke Bleijenberg, Janneke M De Manvan Ginkel, Jaap C A Trappenburg, Roelof Ettema, Carolien G Sino, Noor Heim, Thora B Hafsteindottir, David Richards, Marieke J SchuurmansAbstract:Abstract Background In recent years there has been much emphasis on ‘research waste' caused by poor question selection, insufficient attention to previous research results, and avoidable weakness in research design, conduct and analysis. Little attention has been paid to the effect of inadequate Development of interventions before proceeding to a full clinical trial. Objective We therefore propose to enrich the Development Phase of the MRC Framework by adding crucial elements to improve the likelihood of success and enhance the fit with clinical practice Methods Based on existing intervention Development guidance and synthesis, a comprehensive iterative intervention Development approach is proposed. Examples from published reports are presented to illustrate the methodology that can be applied within each element to enhance the intervention design. Results A comprehensive iterative approach is presented by combining the elements of the MRC Framework Development Phase with essential elements from existing guidance including: problem identification, the systematic identification of evidence, identification or Development of theory, determination of needs, the examination of current practice and context, modelling the process and expected outcomes leading to final element: the intervention design. All elements are drawn from existing models to provide intervention developers with a greater chance of producing an intervention that is well adopted, effective and fitted to the context. Conclusion This comprehensive approach of developing interventions will strengthen the internal and external validity, minimize research waste and add value to health care research. In complex interventions in health care research, flaws in the Development process immediately impact the chances of success. Knowledge regarding the causal mechanisms and interactions within the intended clinical context is needed to develop interventions that fit daily practice and are beneficial for the end-user.
Peggy Zwolinski - One of the best experts on this subject based on the ideXlab platform.
-
a tool to implement sustainable end of life strategies in the product Development Phase
Journal of Cleaner Production, 2008Co-Authors: Alexis Gehin, Peggy Zwolinski, Daniel BrissaudAbstract:Responding to constantly more demanding European legislation, notably for electrical and electronic equipment, worn-out vehicles or hazardous substances, manufacturers have to develop End of Life (EoL) strategies. The challenge today is to assess which ''product EoL process'' would be profitable for an enterprise given the business model in place. Most of the Original Equipment Manufacturers recycle or subcontract reverse logistic and EoL treatments. Recycling is currently the most common solution but it is far from meeting the goals of Sustainable Development. We believe that, integrating constraints from EoL strategies into the early Phases of design is one important aspect that needs to be improved. We are currently combining this idea with principles from concurrent engineering to develop design aids which permits designers to compare their products to ''Remanufacturable Product Profiles''. However, conscious those EoL solutions often involve several strategies; it is now envisaged to develop tools to help designers make optimal decisions while designing a product considering 3R strategies: Reuse, Remanufacture and Recycle. In this paper, our vision of why and how to integrate EoL strategies in the early design Phases is presented, and what tools to apply 3R strategies are envisaged, considering the evolving architecture of the product, and the translation of transversal information into design criteria.
Josy Breuer - One of the best experts on this subject based on the ideXlab platform.
-
safety of gadobutrol results from 42 clinical Phase ii to iv studies and postmarketing surveillance after 29 million applications
Investigative Radiology, 2016Co-Authors: Jan Endrikat, Kai Vogtlaender, Susan Dohanish, Thomas Balzer, Josy BreuerAbstract:ObjectiveThe aim of this study was to provide a systematic safety analysis of gadobutrol after more than 29 million applications in clinical routine.Materials and MethodsForty-two clinical Development Phase II to IV studies on gadobutrol or comparator and the postmarketing safety surveillance databa
